BioPharma Credit (LSE:BPCR) Common Stock : $13.7 Mil (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit Common Stock?

BioPharma Credit's quarterly common stock stayed the same from Dec. 2023 ($13.7 Mil) to Jun. 2024 ($13.7 Mil) and stayed the same from Jun. 2024 ($13.7 Mil) to Dec. 2024 ($13.7 Mil).

BioPharma Credit's annual common stock stayed the same from Dec. 2022 ($13.7 Mil) to Dec. 2023 ($13.7 Mil) and stayed the same from Dec. 2023 ($13.7 Mil) to Dec. 2024 ($13.7 Mil).

BioPharma Credit Common Stock Historical Data

The historical data trend for BioPharma Credit's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPharma Credit Common Stock Chart

BioPharma Credit Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Common Stock

Get a 7-Day Free Trial

13.74

BioPharma Credit Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Common Stock	Get a 7-Day Free Trial											13.74	-	13.74	13.74	13.74

BioPharma Credit Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

BioPharma Credit Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Wellington Street, Central Square, Leeds, GBR, LS1 4DL

Website

https://www.bpcruk.com

BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit Headlines

No Headlines